OBI Pharma, Inc. (TPEX: 4174)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.50
+0.70 (1.25%)
Jan 20, 2025, 1:30 PM CST

OBI Pharma Company Description

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally.

The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; BsADC which is in discovery stage for the treatment of solid tumors.

It also engages in investing and trading; and manufacture and wholesale of western pharmaceuticals, as well as research and development of biotechnology.

OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.

OBI Pharma, Inc.
OBI Pharma logo
Country Taiwan
Founded 2002
Industry Biotechnology
Sector Healthcare
CEO Heidi Wang

Contact Details

Address:
No. 508, Sec. 7
Taipei, 115
Taiwan
Phone 886 2 2655 8799
Website obipharma.com

Stock Details

Ticker Symbol 4174
Exchange Taipei Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency TWD
ISIN Number TW0004174008
SIC Code 2836

Key Executives

Name Position
Dr. Heidi Wang Ph.D. Chief Executive Officer
Dr. Ming-Tain Lai Chief Scientific Officer
Colin Kao Chief Financial Officer, Accounting Supervisor and Corporate Governance Supervisor
Po-Jen Chang Director of Human Resources and Administration
Sharon Lee Director of Public Affairs
Kevin P. Poulos Chief Business Officer of OBI Pharma USA, Inc.
Dr. Wayne Saville M.D. Chief Medical Officer of OBI Pharma USA, Inc.
Dr. Dong Xu Ph.D. Senior Vice President of Biostatistics and Data Management of OBI Pharma USA, Inc.
Chun-Hung Chou Vice President of Chemical Pharmacy and Research & Development Office